Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1178

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1178
---

in the future. From September 26, 2024, through September 26, 2025, the reported sale price of our Common Stock has fluctuated between
$1.91 and $0.13 per share. The stock market in general and the market for biotechnology and technology companies in particular have experienced
extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility,
investors may experience losses on their investment in our Common Stock. The market price of our Common Stock may be influenced by many
factors, including the following:

    ●
    negative publicity;

    ●
    our compliance with Nasdaq rules and regulations;

    ●
    the success of competitive products or technologies;

    ●
    regulatory actions with respect to our product candidates or products or our competitors’ product candidates or products;

47

    ●
    actual or anticipated changes in our growth rate relative to our competitors;

    ●
    announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments;

    ●
    results of clinical studies of our product candidates or those of our competitors;

    ●
    regulatory or legal developments in the U.S. and other countries;

    ●
    developments or disputes concerning patent applications, issued patents or other proprietary rights;

    ●
    the recruitment or departure of key personnel;

    ●
    the level of expenses related to any of our product candidates or clinical development programs;

    ●
    the results of our efforts to in-license or acquire additional product candidates or products;

    ●
    actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

    ●
    variations in our financial results or those of companies that are perceived to be similar to us;

    ●
    fluctuations in the valuation of companies perceived by investors to be comparable to us;

    ●
    inconsistent trading volume levels of our shares;

    ●
    announcement or expectation of additional financing efforts;

    ●
    sales of our Common Stock by us, our insiders or our other stockholders;

    ●
    market conditions in the pharmaceutical and biotechnology sectors;

    ●
    general economic, industry and market conditions; and

    ●
    the other risks described in this “Risk Factors” section.

In addition, the stock markets
in general, and the markets for biotechnology, pharmaceutical and technology stocks in particular, have experienced significant volatility
that has often